Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

RAS/RAF landscape in monoclonal plasma cell conditions

Blood (2024) 144 (2): 201–205.

https://doi.org/10.1182/blood.2023022295

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Xavier Leleu, Jean Fontan, Aurore Perrot, Lionel Karlin, Cyrille Touzeau, Samantha Schulmann, Salomon Manier, Karim Belhadj Merzoug, Adrien Trebouet, Patricia Zunic, Jean Marc Schiano De Colella, Christina Tekle, Marianne Gaucher, Olivier Decaux

Blood (2023) 142 (Supplement 1): 7419.

https://doi.org/10.1182/blood-2023-179532

Published: 2023

Journal Articles

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

Pauline Roché, Gabriel Brisou, Sabine Furst, Robin Noel, Catalina Montes De Oca, Aude Collignon, Luca Inchiappa, Jean Marc Schiano De Colella, Isabelle Brenot Rossi, Thibaut Reichert, Sophie Thévenet, Bechara Mfarrej, Boris Calmels, Didier Blaise, Christian Chabannon, Raynier Devillier

Blood (2022) 140 (Supplement 1): 7740–7741.

https://doi.org/10.1182/blood-2022-157915

Published: 2022

Journal Articles

Autologous Stem Cell Transplant in 2 nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Blood (2022) 140 (Supplement 1): 7712–7713.

https://doi.org/10.1182/blood-2022-158171

Published: 2022

Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Blood (2022) 140 (Supplement 1): 9470–9472.

https://doi.org/10.1182/blood-2022-159586

Published: 2022

Journal Articles

ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Florent Amatore, Nicolas Ortonne, Marc Lopez, Mathilde Barré, Florence Orlanducci, Remy Castellano, Saskia Ingen-Housz-Oro, Amandine De Croos, Laurent Gorvel, Armelle Goubard, Reda Bouabdallah, Jean Marc Schiano De Colella, Jean-Jacques Grob, Philippe Gaulard, Martine Bagot, Armand Bensussan, Emmanuel Delaporte, Daniel Olive

Blood (2021) 138 (Supplement 1): 790.

https://doi.org/10.1182/blood-2021-150677

Published: 2021

Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Blood (2021) 138 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2021-148218

Published: 2021

Journal Articles

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Blood (2021) 138 (Supplement 1): 1387.

https://doi.org/10.1182/blood-2021-150478

Published: 2021

Journal Articles

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

Blood (2021) 138 (Supplement 1): 620.

https://doi.org/10.1182/blood-2021-150953

Published: 2021

Journal Articles

EBV + diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant–related lymphomas

Lénaïg Mescam, Vincent Camus, Jean-Marc Schiano, José Adélaïde, Jean-Michel Picquenot, Arnaud Guille, Marie Bannier, Philippe Ruminy, Pierre-Julien Viailly, Fabrice Jardin, Reda Bouabdallah, Isabelle Brenot-Rossi, Elodie Bohers, Cyrielle Robe, Camille Laurent, Daniel Birnbaum, Andrew Wotherspoon, Philippe Gaulard, Luc Xerri

Blood (2020) 135 (22): 2004–2009.

https://doi.org/10.1182/blood.2019003408

Published: 2020

Includes: Supplemental data

Journal Articles

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Blood (2020) 135 (5): 360–370.

https://doi.org/10.1182/blood.2019001904

Published: 2020

Includes: Supplemental data

Journal Articles

Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

Guillaume Manson, Pauline Brice, Charles Herbaux, MD MSc, Maria Silva, Krimo Bouabdallah, MD, Bénédicte Deau-Fisher, MD, Juliette Bouteloup, MD, Jean Marc Schiano de Collela, MD, Emmanuelle Nicolas-Virelizier, Marie Maerevoet, MD, Herve Ghesquieres, MD PhD, Aspasia Stamatoulas Bastard, Chloe Antier, Florence Poizeau, Laurent Dercle, MD, Roch Houot, MD PhD

Blood (2019) 134 (Supplement_1): 1549.

https://doi.org/10.1182/blood-2019-122171

Published: 2019

Journal Articles

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Blood (2019) 134 (Supplement_1): 4614.

https://doi.org/10.1182/blood-2019-128004

Published: 2019

Journal Articles

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Reid W Merryman, MD, Luca Castagna, MD, Paolo Corradini, MD, Vincent T. Ho, MD, David A. Bond, MD, Samantha Jaglowski, MDMPH, Michael A Spinner, Sally Arai, MD, Robert Lowsky, MD, Alex F. Herrera, MD, Anna Guidetti, MD, Geoffrey Shouse, DO, PhD, Didier Blaise, MD PhD, Jean Marc Schiano De Colella, MD, Talha Badar, MD, Mehdi Hamadani, MD, Stephen M Ansell, MD PhD, Yago Nieto, MD PhD, Chloe Spilleboudt, MD, Tatyana A. Feldman, MD, Lori Dahncke, BSN, Anurag K. Singh, MD, Joseph P. McGuirk, DO, Mohamad Mohty, MD PhD, Remy Dulery, MD, Aspasia Stamatoulas Bastard, Roch Houot, MD PhD, Guillaume Manson, MD, Marie-Pierre Moles, MD, Corentin Orvain, MD, Kamal Bouabdallah, MD, Matthew J. Frigault, MD, Yi-Bin Chen, Ryan C. Lynch, MD, Stephen D. Smith, MD, Uttam Rao, MD, Michael T Byrne, DO, Jason Romancik, MD, Jonathon B. Cohen, MDMS, Robin M. Joyce, MD, Maryam Rahimian, MD, Asad Bashey, MD PhD, Hatcher J. Ballard, BS, Jakub Svoboda, MD, Laura Giordano, Valter Torri, Beatrice Casadei, MD, Martina Sollini, MD, Chiara De Philippis, MD, Massimo Magagnoli, MD, Armando Santoro, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Carmelo Carlo-Stella, MD

Blood (2019) 134 (Supplement_1): 775.

https://doi.org/10.1182/blood-2019-125039

Published: 2019

Journal Articles

Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program

Blood (2018) 132 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2018-99-110960

Published: 2018

Journal Articles

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data

Blood (2018) 132 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2018-99-111659

Published: 2018

Journal Articles

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma

Guillaume Manson, Charles Herbaux, Pauline Brice, Krimo Bouabdallah, Aspasia Stamatoullas, Jean-Marc Schiano, Hervé Ghesquieres, Laurent Dercle, Roch Houot

Blood (2018) 131 (25): 2856–2859.

https://doi.org/10.1182/blood-2018-03-841262

Published: 2018

Journal Articles

Long Term Follow-up of Adults with Burkitt's Lymphoma Receiving Dose-Dense Chemotherapy with or without Rituximab: A Single Center Retrospective 20 Years Study of 51 Patients

Benjamin Bouchacourt, Christophe Zemmour, Diane Coso, Catalina Montes de Oca, Lenaig Mescam, Sylvain Garciaz, Jean Marc Schiano de Collela, Anne-Marie Stoppa, MD, Didier Blaise, Reda Bouabdallah, MD

Blood (2017) 130 (Supplement 1): 5240.

https://doi.org/10.1182/blood.V130.Suppl_1.5240.5240

Published: 2017

Journal Articles

Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation

Virginie Lavoipierre, Samia Harbi, MD, Luca Castagna, MD, Angela Granata, MD, Sabine Fürst, MD, Catherine Faucher, MD, Faezeh Legrand, Stefania Bramanti, MD, Christian Chabannon, MD PhD, Norbert Vey, MD PhD, Jérome Rey, Reda Bouabdallah, MD, Jean Marc Schiano De Colella, Djamel Mokart, Pierre-Jean Weiller, Prof., Didier Blaise, MD PhD, Raynier Devillier, MD PhD

Blood (2016) 128 (22): 4618.

https://doi.org/10.1182/blood.V128.22.4618.4618

Published: 2016

NARROW

RAS/RAF landscape in monoclonal plasma cell conditions

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status in Anti-CD38-Naïve Population

Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study

Autologous Stem Cell Transplant in 2 nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Breast Implant Associated-Anaplastic Large-Cell Lymphoma (BIA-ALCL): Data Based on the Lymphoma Study Association (LYSA) Registry. Promising Results of Brentuximab Vedotin Combined with Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) As First Line Treatment for Patient Requiring Chemotherapy

Salvage Therapy with Brentuximab-Vedotin and Bendamustine for Patients with Relapsed/Refractory T Cell Lymphoma. a Multicenter and Retrospective Study

EBV + diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant–related lymphomas

Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL

Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data

Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma

Long Term Follow-up of Adults with Burkitt's Lymphoma Receiving Dose-Dense Chemotherapy with or without Rituximab: A Single Center Retrospective 20 Years Study of 51 Patients

Haploidentical Stem Cell Transplantation for Patients Relapsing after First Allogeneic Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only